Proceedings Volume 7380 is from: Logo
12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION
11-15 June 2009
Seattle, Washington, United States
Front Matter
Proc. SPIE 7380, Front Matter: Volume 7380, 738001 (5 August 2009); doi: 10.1117/12.839703
Plenary Papers
Proc. SPIE 7380, Taking PDT into mainstream clinical practice, 738005 (13 July 2009); doi: 10.1117/12.828474
Proc. SPIE 7380, Photodynamic application in neurosurgery: present and future, 738007 (13 July 2009); doi: 10.1117/12.823082
PDT Mechanisms of Phototoxicity
Proc. SPIE 7380, Identifying initial molecular targets of PDT: protein and lipid oxidation products, 738008 (1 July 2009); doi: 10.1117/12.827051
Proc. SPIE 7380, Photodynamic therapy: first responses, 738009 (13 July 2009); doi: 10.1117/12.822140
Proc. SPIE 7380, Signaling from lysosomes enhances mitochondria-mediated photodynamic therapy in cancer cells, 73800C (13 July 2009); doi: 10.1117/12.823752
PDT and Immune Responses I
Proc. SPIE 7380, Anti-tumor immune response after photodynamic therapy, 73800F (13 July 2009); doi: 10.1117/12.822994
Proc. SPIE 7380, Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model, 73800H (13 July 2009); doi: 10.1117/12.823005
PDT: Some of the Variables
Proc. SPIE 7380, Intravital fiber-optic fluorescence imaging for monitoring ovarian carcinoma progression and treatment response, 73800L (13 July 2009); doi: 10.1117/12.828206
Proc. SPIE 7380, Variables in photodynamic therapy for Barrett's esophagus, 73800N (13 July 2009); doi: 10.1117/12.822934
Proc. SPIE 7380, Photoreactions for total antioxidant status measurement in humans, 73800O (13 July 2009); doi: 10.1117/12.823472
Clinical PDT I
Proc. SPIE 7380, Efficacy of low-dose mTHPC-PDT for the treatment of basal cell carcinomas, 73800P (13 July 2009); doi: 10.1117/12.822063
Clinical PDT II
Proc. SPIE 7380, Which intracranial lesions would be suitable for fluoresce guided resection?: A prospective review of 110 consecutive lesions, 73800U (13 July 2009); doi: 10.1117/12.822618
Proc. SPIE 7380, Palliative photodynamic therapy for biliary tract carcinoma may improve survival and has a similar outcome to attempted curative surgery with positive resection margins, 73800V (13 July 2009); doi: 10.1117/12.828450
Proc. SPIE 7380, Nanotechnology-based combination therapy improves treatment response in cancer models, 73800W (13 July 2009); doi: 10.1117/12.828402
Photocure Workshop on PDT and PD with Porphyrin Precursors
Proc. SPIE 7380, Apoptotic induction by photodynamic therapy using hexaminolevulinate with a literature review, 73800X (13 July 2009); doi: 10.1117/12.823956
Proc. SPIE 7380, Novel multifunctional acyloxyalkyl ester prodrugs of 5-aminolevulinic acid display improved anticancer activity dependent on photoactivation, 73800Z (13 July 2009); doi: 10.1117/12.822703
Proc. SPIE 7380, Enhancing protoporphyrin IX-induced PDT, 738010 (13 July 2009); doi: 10.1117/12.822241
Proc. SPIE 7380, The effect of ALA/PpIX PDT on putative cancer stem cells in tumor side populations, 738011 (13 July 2009); doi: 10.1117/12.822622
Workshop II
Proc. SPIE 7380, Novel drug delivery strategies for porphyrins and porphyrin precursors, 738013 (13 July 2009); doi: 10.1117/12.822673
Workshop III
Proc. SPIE 7380, ALA PDT for high grade dysplasia in Barrett's oesophagus: review of a decade's experience, 738018 (13 July 2009); doi: 10.1117/12.822976
Workshop IV
Proc. SPIE 7380, Targeted opening of the blood brain barrier by ALA-mediated photodynamic therapy, 73801C (13 July 2009); doi: 10.1117/12.822693
Proc. SPIE 7380, ALA-mediated fluorescence-guided resection (FGR) and PDT of glioma, 73801D (13 July 2009); doi: 10.1117/12.822962
Preclinical I
Proc. SPIE 7380, Novel PDD-PDT system based on spectrophotometric real-time fluorescence monitoring and MALDI-TOF-MS analysis of tumors, 73801I (13 July 2009); doi: 10.1117/12.823247
Clinical PDT III
Proc. SPIE 7380, In-vivo fluorescence dosimetry of aminolevulinate-based protoporphyrin IX (PpIX) accumulation in human nonmelanoma skin cancers and precancers, 73801M (13 July 2009); doi: 10.1117/12.822966
Proc. SPIE 7380, New pain-relieving strategies for topical photodynamic therapy, 73801O (13 July 2009); doi: 10.1117/12.822988
Proc. SPIE 7380, The utilization of a non-invasive fluorescence imaging system to follow clinical dermatological MAL-PDT, 73801P (13 July 2009); doi: 10.1117/12.822756
Clinical PDT IV
Proc. SPIE 7380, Low dose Photofrin PDT for recurrent in-situ squamous cell tumors of the head and neck, 73801R (13 July 2009); doi: 10.1117/12.822259
Proc. SPIE 7380, Photodynamic management of bladder cancer, 73801S (13 July 2009); doi: 10.1117/12.828315
Proc. SPIE 7380, Prevention of bladder tumor implantion after fluorescence-guided TUR with photodynamic therapy, 73801V (13 July 2009); doi: 10.1117/12.828314
Clinical PDT V
Proc. SPIE 7380, A light blanket for intraoperative photodynamic therapy, 73801W (13 July 2009); doi: 10.1117/12.823064
Proc. SPIE 7380, Preliminary study of verteporfin photodynamic therapy in a canine prostate model, 73801Y (13 July 2009); doi: 10.1117/12.822930
Proc. SPIE 7380, Topical application of ALA PDT for the treatment of moderate to severe acne vulgaris, 73801Z (13 July 2009); doi: 10.1117/12.822700
PDT Mechanisms
Proc. SPIE 7380, Using iron chelating agents to enhance dermatological PDT, 738026 (13 July 2009); doi: 10.1117/12.822239
Proc. SPIE 7380, Novel type 1 photosensitizers: viability of leukemia cells exposed to reactive intermediates generated in situ by in vitro photofragmentation, 738027 (13 July 2009); doi: 10.1117/12.822840
Proc. SPIE 7380, The correlation between photosensitizers' membrane localization, membrane-residing targets, and photosensitization efficiency, 738029 (13 July 2009); doi: 10.1117/12.827045
PDT Techniques
Proc. SPIE 7380, Introduction of an ultrathin and flexible laser scanning endoscope for color imaging and integrated PDD and future PDT, 73802A (13 July 2009); doi: 10.1117/12.822734
Sensitizer Synthesis I
Proc. SPIE 7380, Beta-lactamase targeted enzyme activatable photosensitizers for antimicrobial PDT, 73802H (13 July 2009); doi: 10.1117/12.824500
Sensitizer Synthesis II
Proc. SPIE 7380, New porphyrin glyco-conjugates, 73802K (13 July 2009); doi: 10.1117/12.823855
PDT Biophysics and Nanotech
Proc. SPIE 7380, Photodynamic synchrotron x-ray therapy in glioma cell using superparamagnetic iron nanoparticle, 73802P (13 July 2009); doi: 10.1117/12.822919
Clinical PDT VI
Proc. SPIE 7380, Clearance of protoporphyrin IX induced by 5-aminolevulinic acid from WiDr human colon carcinoma cells, 73802Q (13 July 2009); doi: 10.1117/12.822944
Proc. SPIE 7380, New stable synthetic bacteriochlorins for photodynamic therapy of melanoma, 73802S (13 July 2009); doi: 10.1117/12.823060
Proc. SPIE 7380, Selenium enhances the efficacy of Radachlorin-mediated photodynamic therapy in cervical cancer model, 73802T (13 July 2009); doi: 10.1117/12.824242
Clinical PDT VII
Proc. SPIE 7380, Combination of PDT and topical angiogenic inhibitor for treatment of port wine stain (PWS) birthmarks: a novel approach, 73802V (13 July 2009); doi: 10.1117/12.823280
Proc. SPIE 7380, A pilot study comparing the pain sensations during PpIX build-up and clearance phases, 73802Y (13 July 2009); doi: 10.1117/12.822949
Clinical PDT VIII
Proc. SPIE 7380, Results of combined photodynamic therapy (PDT) and high dose rate brachytherapy (HDR) in treatment of obstructive endobronchial non-small cell lung cancer, 73802Z (13 July 2009); doi: 10.1117/12.822837
Proc. SPIE 7380, Photodynamic therapy of cervical intraepithelial neoplasia using hexaminolevulinate and methylaminolevulinate, 738031 (13 July 2009); doi: 10.1117/12.824462
Proc. SPIE 7380, Combination of vascular targeting PDT with combretastatin A4 phosphate, 738032 (13 July 2009); doi: 10.1117/12.822969
Proc. SPIE 7380, HAL fluorescence cystoscopy: towards a new paradigm in bladder cancer management, 738033 (13 July 2009); doi: 10.1117/12.828216
Antimicrobial PDT II
Proc. SPIE 7380, Antimicrobial photodynamic therapy in a mouse model of Acinetobacter baumannii burn infection, 738037 (13 July 2009); doi: 10.1117/12.823065
Proc. SPIE 7380, Investigation into the susceptibility of Burkholderia cepacia complex isolates to photodynamic antimicrobial chemotherapy (PACT), 738039 (13 July 2009); doi: 10.1117/12.822874
Proc. SPIE 7380, Antimicrobial photodynamic therapy for the decolonization of methicillin-resistant Staphylococcus aureus from the anterior nares, 73803B (13 July 2009); doi: 10.1117/12.828279
Antimicrobial PDT III
Proc. SPIE 7380, Influence of bacterial interactions on the susceptibility to photodynamic inactivation, 73803D (13 July 2009); doi: 10.1117/12.822851
Proc. SPIE 7380, Photodynamic dosimetry in the treatment of periodontitis, 73803E (13 July 2009); doi: 10.1117/12.822941
Proc. SPIE 7380, Photodynamic inactivation of antibiotic resistant strain of Pseudomonas aeruginosa in vivo, 73803F (13 July 2009); doi: 10.1117/12.823028
Proc. SPIE 7380, Photochemistry-based immune modulation in the treatment of cutaneous leishmaniasis, 73803G (13 July 2009); doi: 10.1117/12.827041